AUTHORS
Benjamin Baffour Gyau, PhD, Robert E. Miner2, Reginald Atkins, PhD3, Brianna Grossman4, Dimitra M. Tsingelis5, Emily C. Merritt6, Meghan A. Menges7, Jerald D. Noble, PhD8, Luis A. Cuadrado, MSc9, Ryan A. Smolchek10, Jose L. Serrano-Velez11, Greg Sawyer, PhD12, John L Cleveland, PhD13, Jamie K. Teer14, Eric A. Welsh15, John M. Koomen16, Praneeth Reddy Sudalagunta, PhD17, Ariosto Siqueira Silva, PhD18, Mark B. Meads, PhD19, Kenneth H. Shain, MD, PhD20, Frederick L. Locke, MD21, Jennifer M. Binning22, Ciara Louise L Freeman, MD, PhD23
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Moffitt Cancer Center, Tampa, Florida, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction. BCMA-directed CAR T cell and T cell-engager (TCE) therapies are moving into earlier lines of therapy in multiple myeloma (MM), yet responses are neither universal nor indefinite. Ly9 (SLAMF3, CD229) is a SLAM-family receptor that is highly expressed on malignant plasma cells across disease stages and maintained in the relapsed/refractory setting (Freeman et al., ASH 2023). Ly9 is not co-regulated with the plasma cell program driving BCMA downregulation and is thus unaffected by this escape mechanism. Nanobodies (VHH) also offer advantages over scFvs, including smaller size, improved stability/folding, multiplexing potential, reduced immunogenicity, and lower tonic signaling. We hypothesized that a humanized, Ly9-targeting nanobody CAR with concordant fratricide-resistant engineering could overcome resistance and early treatment failure after BCMA-directed therapy.
Methods. Recombinant Ly9 was produced in a Hi5 insect-cell system, biotinylated with BirA, and used to screen a synthetic yeast-display nanobody library. Selected clones were expressed in E. coli with a Twin-Strep tag for biolayer interferometry (BLI) kinetics and flow cytometry staining. Two lead binders were cloned between humanized nanobody framework regions of a clinically validated VHH scaffold, followed by a CD8a hinge and transmembrane domain, and 4-1BB and CD3z endodomains. To mitigate the potential for fratricide, two different LY9 shRNA target sequences were evaluated separately and incorporated into miR-30 flanking regions downstream of CARs using a T2A cleavage sequence. CAR expression, viability, and Ly9 expression kinetics over the course of CAR manufacture were quantified by flow cytometry. Immunoblots were used to determine Ly9 knockdown (KD) efficiency. CAR T persistence and cytotoxicity were assessed by serial-stimulation using the incucyte platform. Also, cytotoxicity assays of four different GFP+ MM cell lines with varying levels of Ly9 and BCMA were performed. In parallel, performance of these novel Ly9 CARs were benchmarked against a BCMA nanobody CAR derived from the cilta-cel patent sequence.
Results. Two Ly9-specific nanobodies, A6 and A11, were identified with selective recognition and BLI-derived affinities of 210 nM and 154 nM, respectively. Subsequent functional studies focused on A6-based construct due to superior detection and quantification. Expression of LY9 on activated T cells created the potential for fratricide following transduction with A6-CAR. Incorporation of an LY9-targeting shRNA (A6-CAR-shLY9) resulted in efficient LY9 knockdown and reduced surface expression, preserved viability (70-90%), and yielded stable CAR expression with no evidence of detectable fratricide throughout manufacturing. In serial stimulation assays (U266 target cells), A6-CAR-shLY9 maintained tumor control through four rounds of repeated challenge, achieving 60-80% tumor elimination compared with 0-5% for untransduced controls (p<0.0001). To evaluate activity across heterogeneous myeloma models, a variety of cell lines were phenotyped by flow cytometry for BCMA expression and selected to represent LY9-high/BCMA-high (MM1S & U226), LY9-low/BCMA-low (8226), and LY9-high/BCMA-negative (U266 BCMA-KO) disease states. A6-CAR-shLY9 demonstrated anti-myeloma activity against all antigen-positive models and remained active over multiple effector-to-target ratios. Most importantly, in the U266 BCMA-KO model, A6-CAR-shLY9 retained durable cytotoxicity and significantly improved tumor control compared with a clinically validated VHH BCMA-directed CAR (p=0.0002).
Conclusions. Ly9 is a stable and homogeneously expressed plasma cell antigen that is essential for myeloma survival and regulated independently of programs governing BCMA, making it an attractive target when BCMA is downregulated or absent. We establish A6-CAR-shLY9 as a manufacturable, humanized, fratricide-resistant nanobody CAR. The incorporation of LY9 knockdown mitigated self-targeting while preserving potent anti-myeloma activity. Importantly, LY9-directed CAR T cells maintained durable cytotoxicity in a BCMA-KO model of antigen escape where BCMA-directed CAR activity was markedly reduced. Together, our findings support Ly9-directed CAR T cells as a promising strategy to overcome BCMA antigen escape and extend the therapeutic reach of cellular immunotherapy in multiple myeloma.
DISCLOSURES
Benjamin Baffour Gyau, PhD: No relevant conflicts of interest to declare.